King Fahad Medical City   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Riyadh City Saudi Arabia (1983)

Organization Overview

First Clinical Trial
2010
NCT01524198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

King Fahad Medical City | King Fahad Specialist Hospital | King Fahad Specialist Hospital Dammam | King Fahad University Hospital | King Fahd Medical City

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 4)

Brain Ischemia (Phase 4)

Cerebral Infarction (Phase 4)

Eclampsia (Phase 2)

Emergencies (Phase 3)

Glioblastoma (Phase 2)

Hepatitis (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Infertility (Phase 2)

Irritable Bowel Syndrome (Phase 4)

Ischemia (Phase 4)

Nervous System Diseases (Phase 4)

Neurologic Manifestations (Phase 4)

Pre-Eclampsia (Phase 2)

Status Asthmaticus (Phase 3)

Stroke (Phase 4)

Trauma, Nervous System (Phase 4)

Vitamin D Deficiency (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 15